Mark Laughlin
Impact in
- Hepatology top 1%
- Hepatitis C virus research
- Epidemiology top 5%
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
Papers in
-
- Hepatitis C virus research 7
-
- HIV/AIDS drug development and treatment 2
- Co-authors
- John Carl Hoefs (1 shared paper)CHRISTIAN G. TREPO (1 shared paper)Mitchell L. Shiffman (1 shared paper)Tobias Heintges (1 shared paper)Karen L. Lindsay (1 shared paper)Zachary D Goodman (1 shared paper)Eugene R. Schiff (1 shared paper)Stuart C. Gordon (1 shared paper)
- Journals
- Journal of Hepatology (3 papers)Hepatology (2 papers)AIDS (1 paper)Clinical Gastroenterology and Hepatology (1 paper)The Journal of Infectious Diseases (1 paper)
- Partner nations
- United StatesFranceAustralia
In The Last Decade
Mark Laughlin
12 papers receiving 1.2k citations
Mark Laughlin's Hit Papers
Peers
Comparison fields: 5 of 73
- Hepatology 978
- Epidemiology 660
- Virology 43
- Rheumatology 93
- Infectious Diseases 116
Countries citing papers authored by Mark Laughlin
This map shows the geographic impact of Mark Laughlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Laughlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Laughlin more than expected).
Fields of papers citing papers by Mark Laughlin
This network shows the impact of papers produced by Mark Laughlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Laughlin. The network helps show where Mark Laughlin may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Laughlin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C Hit paper breakdown → | 2001 | 554 |
| 2 | 2010 | 274 | |
| 3 | 2005 | 117 | |
| 4 | 2006 | 98 | |
| 5 | 2008 | 96 | |
| 6 | 2001 | 51 | |
| 7 | 2002 | 46 | |
| 8 | 1994 | 30 | |
| 9 | 2010 | 16 | |
| 10 | 2010 | 7 | |
| 11 | 2005 | 6 | |
| 12 | A DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF ORAL VERSUS VAGINAL METRONIDAZOLE FOR THE TREATMENT OF TRICHOMONAL VAGINITIS | 1994 | 2 |
About Mark Laughlin
Mark Laughlin is a scholar working on Hepatology, Infectious Diseases, Immunology, Epidemiology and Virology, having authored 12 papers that have together received 1.3k indexed citations. Recurring topics across this work include Hepatitis C virus research (7 papers), Immunodeficiency and Autoimmune Disorders (2 papers), Liver Disease Diagnosis and Treatment (2 papers), HIV/AIDS drug development and treatment (2 papers), Chronic Myeloid Leukemia Treatments (1 paper), Respiratory and Cough-Related Research (1 paper), Neonatal and fetal brain pathology (1 paper) and Urological Disorders and Treatments (1 paper). The work is most often cited by research in Hepatology (978 citations), Epidemiology (660 citations), Virology (43 citations), Rheumatology (93 citations) and Infectious Diseases (116 citations). Mark Laughlin has collaborated with scholars based in United States, France and Australia. Frequent co-authors include John Carl Hoefs, CHRISTIAN G. TREPO, Mitchell L. Shiffman, Tobias Heintges, Karen L. Lindsay, Zachary D Goodman, Eugene R. Schiff, Stuart C. Gordon, Ruji Yao and Janice K. Albrecht. Their work appears in journals such as Journal of Hepatology, Hepatology, AIDS, Clinical Gastroenterology and Hepatology and The Journal of Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.